Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Nov 12;14(11):e242319.
doi: 10.1136/bcr-2021-242319.

Stevens-Johnson syndrome/toxic epidermal necrolysis overlap caused by enzalutamide in patient with metastatic prostate cancer

Jesus Antonio Ocejo Gallegos  1 , Surabhi Amar  2
Affiliations
Case Reports

Stevens-Johnson syndrome/toxic epidermal necrolysis overlap caused by enzalutamide in patient with metastatic prostate cancer

Jesus Antonio Ocejo Gallegos et al. BMJ Case Rep. .
No abstract available

Keywords: dermatology; prostate cancer; skin; unwanted effects / adverse reactions.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
View of the patient’s back with near-complete desquamation and detachment of skin.
Figure 2
Figure 2
Haemorrhagic erosions were noted in the patient’s face and near oral mucosal surfaces. The presence of skin detachment noted in the upper chest.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, et al. . SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149–53. 10.1046/j.1523-1747.2000.00061.x - DOI - PubMed
    1. Ng QX, De Deyn MLZQ, Venkatanarayanan N, et al. . A meta-analysis of cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis. J Inflamm Res 2018;11:135. 10.2147/JIR.S160964 - DOI - PMC - PubMed
    1. Mockenhaupt M, Viboud C, Dunant A, et al. . Stevens–Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-Study. J Invest Dermatol 2008;128:35–44. 10.1038/sj.jid.5701033 - DOI - PubMed
    1. Wu J, Lee YY, Su SC, et al. . Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with malignancies. Br J Dermatol 2015;173:1224–31. 10.1111/bjd.14052 - DOI - PubMed

Publication types